Re: Biogen/Eisai Scrap Aducanumab
in response to
by
posted on
Mar 21, 2019 09:21AM
Other stocks with "plaque related" therapies are declining by association with Biogen. RVX' approach to dementia is different enough that there could be a benefit. I wonder if the company will try to point this out.